Exercise program for breast cancer - Trial ANZCTR12623000973617
Access comprehensive clinical trial information for ANZCTR12623000973617 through Pure Global AI's free database. This Not Applicable trial is sponsored by Westmead Hospital and is currently Not yet recruiting. The study focuses on Breast cancer.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Westmead Hospital
Timeline & Enrollment
Not Applicable
Sep 18, 2023
Sep 02, 2024
Primary Outcome
Quality of life measured by Functional Assessment of Cancer Therapy โ Breast (FACT-B)
Summary
This study aims to evaluate the effectiveness of an individualised exercise program for improving patient-reported health outcomes for quality of life in people with breast cancer. Who is it for? You may be eligible for this study if you are aged 18 years and over, and have received a diagnosis of early-stage breast cancer, are receiving treatment at Westmead Hospital and are able to participate in exercise sessions. Study details Participants will complete an individualised and supervised 12 week exercise program which may be conducted individually, as part of a group at Westmead Hospital or via telehealth at home. The exercise program will consist of a warm up and cool down, and exercises including strengthening. The program duration is 30-60 minutes weekly and for a length of 12 weeks. All participants will undergo physical assessment and complete questionnaires at baseline, 3 months, 6 months and 12 months. Findings from this study will help evaluate the implementation of an exercise program for breast cancer into usual care at Westmead Hospital, as well as identify barriers and enablers to implementation and uptake.
ICD-10 Classifications
Data Source
Australian New Zealand Clinical Trials Registry
ANZCTR12623000973617
Non-Device Trial

